Company news

Voyager Therapeutics, Inc. news in 2024

Voyager Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease

November 19, 2024

Voyager Reports Third Quarter 2024 Financial and Operating Results

November 11, 2024

Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

November 4, 2024

Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected

September 15, 2024

Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14

September 4, 2024

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 28, 2024

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results

August 5, 2024

Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

July 29, 2024

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

June 12, 2024

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

May 15, 2024

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

May 12, 2024

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

May 7, 2024

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

May 5, 2024

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

April 15, 2024

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

March 12, 2024

Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

February 27, 2024

Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

February 25, 2024

Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast

February 20, 2024

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research

February 19, 2024

Voyager Therapeutics Announces Proposed Public Offering

January 3, 2024

Voyager Therapeutics Announces Pricing of Public Offering

January 3, 2024

Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies

January 1, 2024

Calls in 2024

Decks in 2024